Oxford BioTherapeutics has entered a multi‑year collaboration with Bristol Myers Squibb to discover and develop novel T‑cell ...

Bayer has received MHRA approval for Kerendia (finerenone) for adults in the UK with symptomatic chronic heart failure and a left ventricular ejection fraction of 40% or above. Th ...

Subcutaneous delivery shows IV‑level efficacy in moderate to severe TED Amgen has announced positive topline findings from a phase 3 study evaluating a subcutaneous formulation of Tepezza in adults ...

GLP-1 therapies have now advanced far beyond their origins. Originally developed as treatments for type 2 diabetes, they have ...

For decades, progress in IVF has been driven by improvements in process efficiency rather than advances in biology. Clinics ...

CatalYm has dosed the first patient in its global GDFATHER-HCC-01 study, a phase 2b trial evaluating visugromab in combination with chemoimmunotherapy for people with unresectable or metastatic ...

For decades, MASLD has been described as a ‘silent’ condition because it rarely presents with dramatic liver specific ...

Kainova Therapeutics has dosed the first patient in the European expansion of its DOMISOL phase 1/2 trial of DT 7012, a ...

Ardena has announced the appointment of Paul Edwards as Chief People Officer. He will lead Ardena’s global people strategy, ...